A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
Enrolling by invitation · Phase 3 · NCT05735483
Conditions: Atopic Dermatitis, Eczema
At a glance
- Research payments reported, 2025
- $800,680
- U.S. investigators named
- 19
- Sites paid
- 20
- Planned or actual enrollment
- 338
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Lebrikizumab (drug), Placebo (drug)
- Dates
- Started 2023-03-09; completion 2029-04
- Results posted
- Not yet
The main purpose of this study is to assess the long-term safety and efficacy of lebrikizumab in participants 6 Months to \<18 years of age with moderate-to-severe atopic dermatitis. This study will last about 68 weeks and may include up to 16 planned visits. If participating in the optional extension as well, the study will last approximately 1 additional year for a total of up to 116 weeks and may include up to 29 scheduled visits.
From ClinicalTrials.gov, last updated 2026-10-26. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $800,680 in research payments for this study in 2025 (34 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Weily Soong, M.D. Specialist · Birmingham, AL
- Scott M. Dinehart, M.D. Mohs Surgery · Little Rock, AR
- Harper Price, M.D. Dermatology · Phoenix, AZ
- Vivian Laquer, M.D. Dermatology · Irvine, CA
- Jennifer Ornelas Dermatology · Sacramento, CA
- Howard L. Sofen, M.D. Dermatology · Los Angeles, CA
- Jun Lu, MD Dermatology · Farmington, CT
- Pearl C. Kwong, MD PHD Dermatology · Jacksonville, FL
- Elizabeth A. Swanson, M.D. Dermatology · Meridian, ID
- Amy S. Paller, MD Dermatology · Chicago, IL
- Lee S. Clore JR., M.D. Allergy & Immunology · Owensboro, KY
- Brent M. Boyce, M.D. Dermatology · Sebewaing, MI
- Christofer N. Buatti, D.O. Dermatology · Auburn Hills, MI
- Jeffrey G. Leflein, MD Allergy & Immunology · Ypsilanti, MI
- Brian Simmons, MD Dermatology · Lebanon, NH
- Craig A. Rohan, MD Dermatology · Wright Patterson Afb, OH
- Lara Wine Lee, M.D. Dermatology · Charleston, SC
- John C. Browning, MD Dermatology · San Antonio, TX
- Kristen E. Holland, MD Dermatology · Milwaukee, WI
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Medical College of Wisconsin Inc $131,339
- Dermatology Research Associates Inc $120,000
- Osman Dermatology $74,108
- Allergy and Asthma Specialists Psc $64,513
- Texas Dermatology and Laser Specialists $63,768
- University of Connecticut Health $54,828
- Solutions Through Advanced Research $48,978
- Medical University of South Carolina $45,527
- Treasure Valley Medical Research $43,206
- Arkansas Research Trials LLC $22,353
- Respiratory Medicine Research $21,631
- Phoenix Children's Hospital, AZ $21,539
- Northwestern University $19,468
- 113 Efficient Services $19,278
- Wright State Physicians Inc $15,240
- Clinical Research Ctr of Alabama, LLC $14,597
- Oakland Hills Dermatology PC $8,700
- Great Lakes Research Group Inc $6,200
- Dartmouth Hitchcock Clinic $5,129
- Tien Q Nguyen MD Inc DBA First Oc Dermatology $280
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.